Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 16, 2018 06:00 ET | Source: MannKind

United Therapeutics and MannKind Announce Closing of License and Collaboration Agreement

RESEARCH TRIANGLE PARK, N.C. and WESTLAKE VILLAGE, Calif., Oct. 16, 2018 (GLOBE NEWSWIRE) -- United Therapeutics Corporation (Nasdaq: UTHR) and MannKind Corporation (Nasdaq: MNKD) today announced...
October 15, 2018 09:00 ET | Source: MannKind

Afrezza® Inhaled Insulin Television Advertising Campaign Wins Gold Award for Creativity

Broadcast spot recognized at 2018 Medical Marketing & Media (MM&M) Awards WESTLAKE VILLAGE, Calif., Oct. 15, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD), a company focused...
October 04, 2018 09:00 ET | Source: MannKind

MannKind Presents Positive Afrezza® STAT Study Clinical Data at 54th Annual Meeting of the European Association for the Study of Diabetes

Poster 813; PS 068 Improved post-prandial blood glucose excursions with Technosphere inhaled insulin compared to aspart in adult patients with type 1 diabetes: STAT study intention to treat analysis ...
October 03, 2018 09:00 ET | Source: MannKind

MannKind Presents New Scientific Data at 54th Annual Meeting of the European Association for the Study of Diabetes

Presentation 55 Total and severe hypoglycemia is reduced with use of inhaled Technosphere® Insulin (TI) relative to insulin aspart in type 1 diabetes Poster 1046; PS 097 Diabetes duration, BMI, and...
September 24, 2018 09:00 ET | Source: MannKind

MannKind Announces Completion of Cohort 1 and Opens Enrollment for Cohort 2 of Afrezza® Safety and Pharmacokinetics Study in Pediatric Patients

WESTLAKE VILLAGE, Calif., Sept. 24, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) announced today that Cohort 2 of the Afrezza® safety and pharmacokinetics study in pediatric patients...
September 13, 2018 09:00 ET | Source: MannKind

Positive Afrezza® Clinical Data from STAT Study Published in Diabetes Technology & Therapeutics

WESTLAKE VILLAGE, Calif., Sept. 13, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) announced today that "Improved Postprandial Glucose with Inhaled Technosphere® Insulin Compared to...
September 04, 2018 06:00 ET | Source: MannKind

United Therapeutics and MannKind Announce Collaboration for Pulmonary Hypertension Products

Exclusive license agreement for Treprostinil Technosphere®; $95 million in upfront and milestone payments Research agreement for additional products for additional $10 million SILVER SPRING, Md. and...
August 29, 2018 09:00 ET | Source: MannKind

MannKind Corporation to Present at Upcoming Conferences

WESTLAKE VILLAGE, Calif., Aug. 29, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for...
August 02, 2018 16:00 ET | Source: MannKind

MannKind Corporation Reports 2018 Second Quarter Financial Results Conference Call to Begin Today at 5:00 PM ET

2Q 2018 Afrezza Net Revenue was $3.8 million; 142% growth versus 2Q 20172Q 2018 Afrezza TRx grew 71% versus 2Q 2017Debt principal reduced by $42.6 million, or 27%, year-to-dateSuccessfully completed...
July 27, 2018 09:37 ET | Source: MannKind

MannKind and Tanner Pharma Group Enter into an ex-U.S. Distribution Agreement for Afrezza®

WESTLAKE VILLAGE, Calif., July 27, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for...